Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
Moderna Inc (NASDAQ: MRNA) closed the day trading at $30.41 down -2.38% from the previous closing price of $31.15. In other words, the price has decreased by -$2.38 from its previous closing price. On the day, 5.59 million shares were traded. MRNA stock price reached its highest trading level at $31.25 during the session, while it also had its lowest trading level at $30.365.
Ratios:
For a better understanding of MRNA, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.73 and its Current Ratio is at 3.93. In the meantime, Its Debt-to-Equity ratio is 0.08 whereas as Long-Term Debt/Eq ratio is at 0.07.
Upgrades & Downgrades
In the most recent recommendation for this company, Jefferies on December 12, 2025, initiated with a Hold rating and assigned the stock a target price of $30.
On March 13, 2025, Citigroup started tracking the stock assigning a Neutral rating and target price of $40.
Barclays Downgraded its Overweight to Equal Weight on February 18, 2025, whereas the target price for the stock was revised from $111 to $45.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Dec 11 ’25 when AFEYAN NOUBAR sold 23,853 shares for $29.48 per share. The transaction valued at 703,306 led to the insider holds 3,924 shares of the business.
Flagship Pioneering Inc. bought 23,853 shares of MRNA for $703,306 on Dec 11 ’25. On Dec 09 ’25, another insider, Hussain Abbas, who serves as the Director of the company, sold 504 shares for $27.60 each. As a result, the insider received 13,910 and left with 1,515 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, MRNA now has a Market Capitalization of 11882209280 and an Enterprise Value of 8110563840. For the stock, the TTM Price-to-Sale (P/S) ratio is 5.32 while its Price-to-Book (P/B) ratio in mrq is 1.27. Its current Enterprise Value per Revenue stands at 3.634 whereas that against EBITDA is -2.492.
Stock Price History:
The Beta on a monthly basis for MRNA is 1.18, which has changed by -0.25833333 over the last 52 weeks, in comparison to a change of 0.17673707 over the same period for the S&P500. Over the past 52 weeks, MRNA has reached a high of $48.92, while it has fallen to a 52-week low of $22.28. The 50-Day Moving Average of the stock is 12.31%, while the 200-Day Moving Average is calculated to be 10.88%.
Shares Statistics:
Over the past 3-months, MRNA traded about 10.66M shares per day on average, while over the past 10 days, MRNA traded about 10562670 shares per day. A total of 391.00M shares are outstanding, with a floating share count of 357.38M. Insiders hold about 8.54% of the company’s shares, while institutions hold 70.19% stake in the company. Shares short for MRNA as of 1765756800 were 69679477 with a Short Ratio of 6.53, compared to 1763078400 on 64356094. Therefore, it implies a Short% of Shares Outstanding of 69679477 and a Short% of Float of 21.68.
Earnings Estimates
The stock of Moderna Inc (MRNA) is currently drawing attention from 11.0 analysts actively involved in the ongoing evaluation and rating process.The consensus estimate for the next quarter is -$2.32, with high estimates of -$1.85 and low estimates of -$2.83.
Analysts are recommending an EPS of between -$7.47 and -$9.54 for the fiscal current year, implying an average EPS of -$8.07. EPS for the following year is -$7.05, with 18.0 analysts recommending between -$4.47 and -$8.37.
Revenue Estimates
13 analysts predict $633.09M in revenue for. The current quarter. It ranges from a high estimate of $836.4M to a low estimate of $467M. As of. The current estimate, Moderna Inc’s year-ago sales were $966MFor the next quarter, 13 analysts are estimating revenue of $235.15M. There is a high estimate of $471M for the next quarter, whereas the lowest estimate is $58.1M.
A total of 21 analysts have provided revenue estimates for MRNA’s current fiscal year. The highest revenue estimate was $2.1B, while the lowest revenue estimate was $1.73B, resulting in an average revenue estimate of $1.9B. In the same quarter a year ago, actual revenue was $3.24BBased on 21 analysts’ estimates, the company’s revenue will be $1.95B in the next fiscal year. The high estimate is $2.34B and the low estimate is $1.36B.
